Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

- Advances Achieved in All Clinical Programs, With Three Bavituximab Phase

II Cancer Trials Ongoing - - Updated Initial Data from Bavituximab Plus Docetaxel Phase II Breast Cancer Trial Shows at Least 9 of 14 Evaluable Patients Achieved a Partial

Tumor Response - - Company Begins Work under Contract with Defense Threat Reduction Agency

Potentially Worth Up to $44.4 Million -

TUSTIN, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2009 ended July 31, 2008. The company reported a consolidated net loss of $5,086,000, or $0.02 per basic and diluted share, compared to a consolidated net loss of $4,656,000 or $0.02 per basic and diluted share for the same prior year period. The increased net loss primarily reflects increased investments in research and development as the company advanced its clinical programs for bavituximab and Cotara(R).

Total revenues for the current quarter were $1,517,000 compared to $1,625,000 for the comparable quarter last year and were primarily generated from services provided by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary. Total revenues for the quarter also include the first government contract revenues generated by Peregrine's contract with the Defense Threat Reduction Agency (DTRA), potentially worth up to $44.4 million over a period of up to five years to evaluate bavituximab for the prevention or treatment of viral hemorrhagic fever infections.

Total costs and expenses increased to $6,677,000 in the first quarter of FY 2009 from $6,513,000 in the same prior year
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... May 16, 2013  HealthSparq, a trusted provider ... nation,s largest regional health plans, will debut a ... Plans (AHIP) Institute 2013 conference on June 13. ... showing how health insurance companies across the country ... and marketplace demands for increased healthcare transparency. ...
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
(Date:5/16/2013)... Toronto, Canada (PRWEB) May 16, 2013 ... years and costs over one billion dollars. Despite this ... market. With stakes this high, is your clinical trial ... and deliver the best outcomes? , Dr. Frederic Sax, ... Quintiles, will discuss the use of data, information and ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces ... is available in its catalogue: ... for Acute Coronary Syndromes - APAC ... http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic MediPoint: ... Syndromes - APAC Analysis and Market ...
Breaking Biology Technology:HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8
... List -- SHANGHAI, Aug. 26 /PRNewswire-Asia-FirstCall/ -- ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... CEO and CFO -- LONDON, August 26, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... potato chips or pop in a DVD, you,re probably putting your ... Sputter deposition is an industrial process used since the 1970s to ... like the metallic coating on potato chip bags, the reflective surface ... process works very well. In a vacuum chamber filled with an ...
Cached Biology Technology:China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 2China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 3China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 4China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 5China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 6China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 7Hikma - Half Year Results Interviews With CEO and CFO 2Hikma - Half Year Results Interviews With CEO and CFO 3Hikma - Half Year Results Interviews With CEO and CFO 4Hikma - Half Year Results Interviews With CEO and CFO 5Trouble with sputter? Blame giant nanoparticles 2Trouble with sputter? Blame giant nanoparticles 3
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
(Date:5/16/2013)... about 23 million years old give unprecedented insight ... one of the most species-rich groups among the ... Professor Bettina Reichenbacher from the Division of Paleontology ... Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich / ... fossils which they assign to the group of ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... LOUISVILLE, Ky. A University of Louisville scientist has determined ... disease manipulates our cells to generate the amino acids it ... lungs. The results are published online today (Nov. 17) in ... Endowed Professor in Molecular Pathogenesis of Microbial Infections at UofL, ...
... character just hidden from view, a mystery atom in ... long hindered scientists, ability to study the enzyme fully. ... by Serena DeBeer, Cornell assistant professor of chemistry and ... synchrotron spectroscopy and computational modeling to reveal carbon as ...
... MINNEAPOLIS, Nov. 17, 2011 Minntech Corporation has been ... Life Sciences - Established Companies Category. Presented by the ... companies and individuals who have played a significant role ... and futures of people living around the world. ...
Cached Biology News:UofL researcher determines how Legionnaires' bacteria proliferate, cause disease 2UofL researcher determines how Legionnaires' bacteria proliferate, cause disease 3In an enzyme critical for life, X-ray emission cracks mystery atom 2Minntech Corporation Receives 2011 Tekne Award 2Minntech Corporation Receives 2011 Tekne Award 3
...
... ZMD.366. Immunogen: Synthetic peptide ... of human SENP1. Specificity: ... kDa SENP1. Reactivity: Human ... transfected Hep2 cell lysates HL-60 ...
...
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
Biology Products: